Related Experiment Videos

Emerging fungal pathogens in patients with hematologic malignancies and marrow/stem-cell transplant recipients

Balkrishna N Jahagirdar1, Vicki A Morrison

  • 1Section of Hematology, Oncology, and Transplantation, University of Minnesota, USA.

Seminars in Respiratory Infections
|June 19, 2002
PubMed

Insights

Rare fungal infections pose significant risks for immunocompromised patients, including those with hematologic malignancies and stem-cell transplant recipients. This review details the epidemiology, clinical features, and management of infections caused by unusual fungal pathogens.

Area of Science:

  • Medical Mycology
  • Infectious Diseases
  • Hematology

Background:

  • Fungal infections are a significant cause of morbidity and mortality in immunocompromised patients, particularly those with hematologic malignancies and hematopoietic stem-cell transplant (HSCT) recipients.
  • While Candida and Aspergillus are common, infections by unusual fungal pathogens are increasingly recognized in these vulnerable populations.

Purpose of the Study:

  • To summarize the epidemiology, pathogenesis, clinical features, and management strategies for infections caused by a range of uncommon fungal pathogens.
  • To highlight the importance of early diagnosis and prompt treatment for successful outcomes.

Main Methods:

  • Review of current literature on fungal infections in immunocompromised hosts.
  • Synthesis of information on epidemiology, pathogenesis, clinical presentations, and treatment approaches for specific rare fungal genera.

Main Results:

  • Unusual fungal pathogens like Fusarium, Zygomycetes, Scedosporium, Trichosporon, Malassezia, Alternaria, Paecilomyces, and Penicillium cause distinct clinical syndromes.
  • These infections require timely diagnosis and specific management due to their potential severity.

Conclusions:

  • Recognizing the spectrum of disease caused by rare fungi is crucial for effective management in high-risk patient groups.
  • Prompt diagnosis and targeted therapy are essential for improving outcomes in patients with these invasive fungal infections.

Related Concept Videos